middle.news
How EVE Health’s Libbo and Dyspro Are Poised to Transform Australian Health Markets
9:38am on Monday 21st of July, 2025 AEST
•
Healthcare
Read Story
How EVE Health’s Libbo and Dyspro Are Poised to Transform Australian Health Markets
9:38am on Monday 21st of July, 2025 AEST
Key Points
Regulatory approval achieved for Libbo (ED) and Dyspro (dysmenorrhoea) under TGA pathways
First commercial batch purchase order for Dyspro submitted
National prescriber coverage established via telehealth and GP clinics
Commercial launch in Australia targeted before end of 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Eve Health (ASX:EVE)
OPEN ARTICLE